Thor Medical

Company profile

Thor Medical company profile

Thor Medical ASA is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics. The company's lead clinical-stage product is Betalutin®, the first in a new class of antibody radionuclide conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities. Betalutin® is a tumour-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (lutetium-177). It is showing promising efficacy and tolerability in a Phase 1/2 clinical study in a difficult-to-treat NHL patient population. The company aims to develop Betalutin® for the treatment of patients with relapsed/refractory NHL. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. Nordic Nanovector is committed to building a pipeline of novel ARCs and antibody drug conjugates (ADCs) addressing multiple selected haematological malignancies based on proprietary technologies and expertise, and with technologies from partners where complementary.